What can we learn from the ZOOM trial?


1 Amadori D, Aglietta M, Alessi B, et al. Effi cacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 2013; 14: 663–70. 2 Martin M, López-Tarruella S. Zooming in on the schedule of bone-modifying… (More)
DOI: 10.1016/S1470-2045(13)70345-0